p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer

Kirsti Husgafvel-Pursiainen, Paolo Boffetta, Annamaria Kannio, Fredrik Nyberg, Göran Pershagen, Anush Mukeria, Vali Constantinescu, Cristina Fortes, Simone Benhamou

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Biomarker data may provide a way to strengthen the link between environmental tobacco smoke (ETS) exposure and lung cancer shown in epidemiological studies. We conducted a multicenter case-control study to investigate the association between ETS exposure and lung cancer in never- smokers using p53 mutations as a biomarker of tobacco-related carcinogenesis. Paraffin-embedded tissue or fresh tissue samples from 91 never-smokers and 66 smokers with histologically confirmed lung cancer and interview data about smoking habits and ETS exposure were analyzed for mutations in the p53 gene. Statistical analysis was performed using multivariate logistic regression. Among the lifelong nonsmokers, the overall mutation prevalence was 10% (nine cases). Among 48 neversmokers ever exposed to spousal ETS, 13% (six cases) showed mutations. Smokers exhibited 17 (26%) mutations. A 3-fold [odds ratio, 2.9; 95% confidence interval (CI), 1.2-7,2] increased risk of p53 mutation was observed for smokers as compared with all never-smokers combined (i.e., irrespective of ETS exposure). The increase was 4.4-fold (95% CI, 1.216.2) when compared with never-smokers without ETS exposure. Among never-smokers, the risk of mutation was doubled (odds ratio, 2.0; 95% CI, 0.5-8.7) for exposure to spousal ETS only, based on 6 exposed cases with mutation and 42 exposed cases without mutation. The risk was 1.5 (95% CI, 0.2-8.8) for those ever exposed to spousal or workplace ETS as compared with those never exposed to spousal or workplace ETS. For smokers, the most common mutation type was G:C to T:A transversion (31%), whereas G:C to A:T transitions were predominant among never smokers (57%). In conclusion, our study indicates a significant 3-4-fold increased risk of p53 mutation in smoking lung cancer cases, and it suggests that mechanisms of lung carcinogenesis in ETS-exposed neversmokers include mutations in the p53 gene, similar to that seen in smokers. However, the mutation patterns observed also suggest a difference between smokers and never-smokers. Clearly, additional investigations of the role of p53 mutation as a biomarker for tobacco-related carcinogenesis, including that related to ETS, are indicated.

Original languageEnglish
Pages (from-to)2906-2911
Number of pages6
JournalCancer Research
Volume60
Issue number11
Publication statusPublished - Jun 1 2000

Fingerprint

Environmental Exposure
Smoke
Multicenter Studies
Tobacco
Lung Neoplasms
Mutation
Confidence Intervals
Carcinogenesis
Biomarkers
p53 Genes
Workplace
Smoking
Odds Ratio
Paraffin
Habits
Case-Control Studies
Epidemiologic Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Husgafvel-Pursiainen, K., Boffetta, P., Kannio, A., Nyberg, F., Pershagen, G., Mukeria, A., ... Benhamou, S. (2000). p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Research, 60(11), 2906-2911.

p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. / Husgafvel-Pursiainen, Kirsti; Boffetta, Paolo; Kannio, Annamaria; Nyberg, Fredrik; Pershagen, Göran; Mukeria, Anush; Constantinescu, Vali; Fortes, Cristina; Benhamou, Simone.

In: Cancer Research, Vol. 60, No. 11, 01.06.2000, p. 2906-2911.

Research output: Contribution to journalArticle

Husgafvel-Pursiainen, K, Boffetta, P, Kannio, A, Nyberg, F, Pershagen, G, Mukeria, A, Constantinescu, V, Fortes, C & Benhamou, S 2000, 'p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer', Cancer Research, vol. 60, no. 11, pp. 2906-2911.
Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A et al. p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Research. 2000 Jun 1;60(11):2906-2911.
Husgafvel-Pursiainen, Kirsti ; Boffetta, Paolo ; Kannio, Annamaria ; Nyberg, Fredrik ; Pershagen, Göran ; Mukeria, Anush ; Constantinescu, Vali ; Fortes, Cristina ; Benhamou, Simone. / p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. In: Cancer Research. 2000 ; Vol. 60, No. 11. pp. 2906-2911.
@article{bca89aee9823425ab441730d3839f50b,
title = "p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer",
abstract = "Biomarker data may provide a way to strengthen the link between environmental tobacco smoke (ETS) exposure and lung cancer shown in epidemiological studies. We conducted a multicenter case-control study to investigate the association between ETS exposure and lung cancer in never- smokers using p53 mutations as a biomarker of tobacco-related carcinogenesis. Paraffin-embedded tissue or fresh tissue samples from 91 never-smokers and 66 smokers with histologically confirmed lung cancer and interview data about smoking habits and ETS exposure were analyzed for mutations in the p53 gene. Statistical analysis was performed using multivariate logistic regression. Among the lifelong nonsmokers, the overall mutation prevalence was 10{\%} (nine cases). Among 48 neversmokers ever exposed to spousal ETS, 13{\%} (six cases) showed mutations. Smokers exhibited 17 (26{\%}) mutations. A 3-fold [odds ratio, 2.9; 95{\%} confidence interval (CI), 1.2-7,2] increased risk of p53 mutation was observed for smokers as compared with all never-smokers combined (i.e., irrespective of ETS exposure). The increase was 4.4-fold (95{\%} CI, 1.216.2) when compared with never-smokers without ETS exposure. Among never-smokers, the risk of mutation was doubled (odds ratio, 2.0; 95{\%} CI, 0.5-8.7) for exposure to spousal ETS only, based on 6 exposed cases with mutation and 42 exposed cases without mutation. The risk was 1.5 (95{\%} CI, 0.2-8.8) for those ever exposed to spousal or workplace ETS as compared with those never exposed to spousal or workplace ETS. For smokers, the most common mutation type was G:C to T:A transversion (31{\%}), whereas G:C to A:T transitions were predominant among never smokers (57{\%}). In conclusion, our study indicates a significant 3-4-fold increased risk of p53 mutation in smoking lung cancer cases, and it suggests that mechanisms of lung carcinogenesis in ETS-exposed neversmokers include mutations in the p53 gene, similar to that seen in smokers. However, the mutation patterns observed also suggest a difference between smokers and never-smokers. Clearly, additional investigations of the role of p53 mutation as a biomarker for tobacco-related carcinogenesis, including that related to ETS, are indicated.",
author = "Kirsti Husgafvel-Pursiainen and Paolo Boffetta and Annamaria Kannio and Fredrik Nyberg and G{\"o}ran Pershagen and Anush Mukeria and Vali Constantinescu and Cristina Fortes and Simone Benhamou",
year = "2000",
month = "6",
day = "1",
language = "English",
volume = "60",
pages = "2906--2911",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - p53 Mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer

AU - Husgafvel-Pursiainen, Kirsti

AU - Boffetta, Paolo

AU - Kannio, Annamaria

AU - Nyberg, Fredrik

AU - Pershagen, Göran

AU - Mukeria, Anush

AU - Constantinescu, Vali

AU - Fortes, Cristina

AU - Benhamou, Simone

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Biomarker data may provide a way to strengthen the link between environmental tobacco smoke (ETS) exposure and lung cancer shown in epidemiological studies. We conducted a multicenter case-control study to investigate the association between ETS exposure and lung cancer in never- smokers using p53 mutations as a biomarker of tobacco-related carcinogenesis. Paraffin-embedded tissue or fresh tissue samples from 91 never-smokers and 66 smokers with histologically confirmed lung cancer and interview data about smoking habits and ETS exposure were analyzed for mutations in the p53 gene. Statistical analysis was performed using multivariate logistic regression. Among the lifelong nonsmokers, the overall mutation prevalence was 10% (nine cases). Among 48 neversmokers ever exposed to spousal ETS, 13% (six cases) showed mutations. Smokers exhibited 17 (26%) mutations. A 3-fold [odds ratio, 2.9; 95% confidence interval (CI), 1.2-7,2] increased risk of p53 mutation was observed for smokers as compared with all never-smokers combined (i.e., irrespective of ETS exposure). The increase was 4.4-fold (95% CI, 1.216.2) when compared with never-smokers without ETS exposure. Among never-smokers, the risk of mutation was doubled (odds ratio, 2.0; 95% CI, 0.5-8.7) for exposure to spousal ETS only, based on 6 exposed cases with mutation and 42 exposed cases without mutation. The risk was 1.5 (95% CI, 0.2-8.8) for those ever exposed to spousal or workplace ETS as compared with those never exposed to spousal or workplace ETS. For smokers, the most common mutation type was G:C to T:A transversion (31%), whereas G:C to A:T transitions were predominant among never smokers (57%). In conclusion, our study indicates a significant 3-4-fold increased risk of p53 mutation in smoking lung cancer cases, and it suggests that mechanisms of lung carcinogenesis in ETS-exposed neversmokers include mutations in the p53 gene, similar to that seen in smokers. However, the mutation patterns observed also suggest a difference between smokers and never-smokers. Clearly, additional investigations of the role of p53 mutation as a biomarker for tobacco-related carcinogenesis, including that related to ETS, are indicated.

AB - Biomarker data may provide a way to strengthen the link between environmental tobacco smoke (ETS) exposure and lung cancer shown in epidemiological studies. We conducted a multicenter case-control study to investigate the association between ETS exposure and lung cancer in never- smokers using p53 mutations as a biomarker of tobacco-related carcinogenesis. Paraffin-embedded tissue or fresh tissue samples from 91 never-smokers and 66 smokers with histologically confirmed lung cancer and interview data about smoking habits and ETS exposure were analyzed for mutations in the p53 gene. Statistical analysis was performed using multivariate logistic regression. Among the lifelong nonsmokers, the overall mutation prevalence was 10% (nine cases). Among 48 neversmokers ever exposed to spousal ETS, 13% (six cases) showed mutations. Smokers exhibited 17 (26%) mutations. A 3-fold [odds ratio, 2.9; 95% confidence interval (CI), 1.2-7,2] increased risk of p53 mutation was observed for smokers as compared with all never-smokers combined (i.e., irrespective of ETS exposure). The increase was 4.4-fold (95% CI, 1.216.2) when compared with never-smokers without ETS exposure. Among never-smokers, the risk of mutation was doubled (odds ratio, 2.0; 95% CI, 0.5-8.7) for exposure to spousal ETS only, based on 6 exposed cases with mutation and 42 exposed cases without mutation. The risk was 1.5 (95% CI, 0.2-8.8) for those ever exposed to spousal or workplace ETS as compared with those never exposed to spousal or workplace ETS. For smokers, the most common mutation type was G:C to T:A transversion (31%), whereas G:C to A:T transitions were predominant among never smokers (57%). In conclusion, our study indicates a significant 3-4-fold increased risk of p53 mutation in smoking lung cancer cases, and it suggests that mechanisms of lung carcinogenesis in ETS-exposed neversmokers include mutations in the p53 gene, similar to that seen in smokers. However, the mutation patterns observed also suggest a difference between smokers and never-smokers. Clearly, additional investigations of the role of p53 mutation as a biomarker for tobacco-related carcinogenesis, including that related to ETS, are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0034213247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034213247&partnerID=8YFLogxK

M3 - Article

C2 - 10850436

AN - SCOPUS:0034213247

VL - 60

SP - 2906

EP - 2911

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 11

ER -